The University of Tokyo · Economics, Econometrics and Finance
Professor Toshiaki Iizuka's research lab specializes in health economics and industrial organization, with a focus on physician agency, pharmaceutical market dynamics, and the impact of marketing and policy on healthcare decisions. The lab investigates how financial incentives, such as drug mark-ups and direct-to-consumer advertising, influence prescribing behaviors and patient outcomes in Japan and the U.S. Key research directions include the adoption of generic drugs, the role of promotional activities in shaping formulary choices, and the strategic behavior of durable goods producers, particularly in textbook markets. The lab combines microeconomic theory with empirical analysis using detailed panel and survey data to inform health policy and market regulation.
Figures are computed from collected data and may differ slightly.
This article examined the physician-patient agency relationship in the context of the prescription drug market in Japan. In this market, physicians often both prescribe and dispense drugs and can pocket profits in so doing. A concern is that, due to the incentive created by the mark-up, physicians' prescription decisions may be distorted. Empirical results using anti-hypertensive drugs suggest that physicians' prescription choices are influenced by the mark-up. However, physicians are also sensi
The dramatic increase of direct‐to‐consumer advertising (DTCA) of prescription drugs created intensive debates on its effects on patient and doctor behaviors. Combining 1994–2000 DTCA data with the 1995–2000 National Ambulatory Medical Care Surveys, we examine the effect of DTCA on doctor visits. Consistent with the proponents' claim, we find that higher DTCA expenditures are associated with increased doctor visits, especially after the Food and Drug Administration clarified DTCA rules in August
I examine physician agency in health care services in the context of the choice between brand-name and generic pharmaceuticals. I examine micro-panel data from Japan, where physicians can legally make profits by prescribing and dispensing drugs. The results indicate that physicians often fail to internalize patient costs, explaining why cheaper generics are infrequently adopted. Doctors respond to markup differentials between the two versions, indicating another agency problem. However, generics
A reliable conversion factor for the infrared absorptiometry of oxygen in silicon has been determined by round‐robin infrared measurement followed by charged particle activation analysis with the reaction. As for the round‐robin samples, 70 dislocation‐free CZ silicon wafers with oxygen contents ranging from and thicknesses of 2, 1, and 0.5 mm were carefully prepared by five organizations. A good linear relationship has been obtained between the absorption coefficient and the oxygen content. The
This paper examines the effect of direct‐to‐consumer advertising (DTCA) of prescription drugs on doctors' choice of drug brands. Using antihistamines as an example, we show that DTCA has little effect on the choice of brand despite the massive DTCA expenditure incurred in this class. In contrast, promotional activities directed toward physicians have larger and longer lasting effects. These results, together with the market‐expanding results shown in Iizuka and Jin (2005), suggest that DTCA is e
This paper examines the decision to introduce new products by durable goods producers. Conventional wisdom suggests that durable goods producers introduce new products to kill off used products. However, used units may not compete with new units if initial price can capture the present value of all future transactions. Using new data from the textbook market, I find that publishers revise editions more frequently when competition from used textbooks increases. This suggests the presence of plann
Do consumers react differently to zero prices? We test the presence of a zero-price effect in child health care and find that a zero price is special as it boosts demand discontinuously. A zero price affects resource allocations by encouraging healthier children to use more services and exacerbates behavioral hazard by increasing inappropriate use of antibiotics. A co-payment, of as small as US$2 per visit, alleviates these problems without substantially increasing financial risk. However, a zer
An important objective of medical liability law is to deter medical errors by punishing negligent mistakes. However, relatively little evidence exists on the deterrence effect. Using newly constructed measures of preventable medical complications and state tort reforms in the United States between 1994 and 2007, I find evidence that higher liability pressure deters preventable medical complications associated with four specific obstetric and gynecologic procedures. The results also show that the
The dramatic increase of direct-to-consumer advertising (DTCA) of prescrip-tion drugs created intensive debates on its effects on patient and doctor behaviors. Combining 1994–2000 DTCA data with the 1995–2000 National Ambulatory Medical Care Surveys, we examine the effect of DTCA on doctor visits. Consistent with the proponents ’ claim, we find that higher DTCA expenditures are associated with increased doctor visits, especially after the Food and Drug Administration clarified DTCA rules in Augu
We investigate the marginal value of information in the context of health signals that people receive after checkups. Although underlying health status is similar for individuals just below and above a clinical threshold, treatments differ according to the checkup signals they receive. For the general population, whereas health warnings about diabetes increase healthcare utilization, health outcomes do not improve. However, among high-risk individuals, outcomes do improve, and improved health is
Open papers in the app to read, cite, and organize with AI.